Palobiofarma

Barcelona, Spain · Founded 2005 · Privately Held (backing)

Developer of adenosine receptor modulators designed to advance treatments for orphan and neurological diseases. Palobiofarma is based in Barcelona, Spain and was founded in 2005. Its last known valuation is $79.3 million. It has raised $21.1 million.

Last price · $/share
—
Implied valuation
$79.3M
Total raised
$21.1M
Last round
—
What is Palobiofarma worth?
$79.3Mlast known valuation
Free account
More of Palobiofarma with a free account
  • ·The complete investor list: 15 names
  • ·Watch Palobiofarma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Palobiofarma funding history

No rounds on record

No funding rounds for Palobiofarma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Palobiofarma valuation

Palobiofarma's last known valuation is $79.3 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How Palobiofarma's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Palobiofarma, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about Palobiofarma

What is Palobiofarma worth?
Palobiofarma's last known valuation is $79.3M.
How much has Palobiofarma raised?
Palobiofarma has raised $21.1M in total funding across its recorded rounds.